engineered mitochondria vaccine

The **engineered mitochondria vaccine** is an investigational cancer vaccine in early clinical development that utilizes mitochondria, genetically engineered to express specific tumor antigens, as the immunogenic platform. The approach leverages unique innate immunostimulatory properties of mitochondria, which release damage-associated molecular patterns (DAMPs), including mitochondrial DNA and proteins, capable of activating innate immune pathways (e.g., through pattern recognition receptors such as TLRs and NLRs). The engineered mitochondria serve both as carriers of tumor-specific or tumor-associated antigens and as potent adjuvants, stimulating both innate and adaptive immune responses. The vaccine is designed to elicit robust anti-tumor immunity in patients with advanced solid tumors, with the potential to inhibit tumor growth and metastasis. It is currently undergoing evaluation in a phase 1 dose-escalation clinical trial for safety, tolerability, and preliminary efficacy in advanced solid tumors[2][4][8].

Other names

engineered mitochondrial vaccine